• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Eva Maria Amoah
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

ECJ verdict in SPC dispute over Gileads AIDS blockbuster

25. July 2018

The ECJ today delivered a ruling on Gilead’s AIDS blockbuster TRUVADA®. It is about the delicate determination of the criteria when an active substance of a drug is “protected by a valid basic patent” and thus about an important decision for SPC.

SPC in focus

AIDS BlockbusterThe focus of the dispute was the legal status of the supplementary protection certificate (SPC) for the combination drug and blockbuster AIDS preparation TRUVADA®, which is approved for HIV treatment and so-called pre-exposure prophylaxis (PREP). It is also the only drug approved for the prevention of HIV infection, and is therefore also considered a key drug for public health in relation to HIV infection. It was also approved for generic manufacturers in 2017.

Gilead resisted the generic approval of the AIDS blockbuster in court. The American pharmaceutical company sees its patent protection, which is protected by an SPC, infringed by the manufacturers of generic drugs. Truvada® combines the active ingredients tenofovirdisoproxil and emtricitabine. The active ingredient emtricitabine is also protected by the basic patent. However, it is controversial whether the combination of active ingredients with emtricitabine is also protected by patent, since this combination is the subject of Gilead’s SPC attack.

Advocate General argued in favour of a narrow interpretation

Today’s ruling follows the opinion of Advocate General Melchior Wathelet on the interpretation of Article 3 of Regulation No 469/2009 at the end of April, who recommended to the European Court of Justice (ECJ) that protection certificates should not be granted for active substances which are not mentioned in the wording of the basic patent. Rather, each active substance must be “specific and precisely identifiable in the wording of the patent claims on the priority date of the patent”.

Today’s judgment of the ECJ

The ECJ confirmed this interpretation in today’s judgment in large parts. A product consisting of several active substances with combined action is protected “by a valid basic patent” for the purposes of this provision, even if the combination of active substances of which this product consists is not expressly mentioned in the claims of the basic patent, those claims relate necessarily and specifically to that combination.

An active substance which corresponds to a functional definition contained in the claims of a granted European basic patent may be considered to be protected by that patent – if the claims relate to that active substance. That is a matter for the national referring court to determine.

For this purpose, from an expert’s point of view and on the basis of the prior art on the filing date or priority date of the basic patent facts must be fulfilled as follows:

  • the combination of those active ingredients must necessarily, in the light of the description and drawings of that patent, fall under the invention covered by that patent, and
  • each of those active ingredients must be specifically identifiable, in the light of all the information disclosed by that patent.

With this ruling, Gilead not only loses its protection certificate for Truvada as it has provisionally done in Germany (see info blog: Gilead loses patent protection for AIDS blockbuster TRUVADA®), but will probably lose it Europe-wide. The British Patent Court had asked the Court in Luxembourg for a clear interpretation of the regulation. This actual patent dispute will therefore be brought to an end before the British court.

 

Do You want help or protection for your trademark or brand?

Our lawyers advise you individually and together with you develop the right strategy to protect your trademark.

CAT-call_en
Sources:

Curia Europe: Teva Gilead

Picture:

mizianitak / pixabay.com/ CCO License

  • share  
  • share 
  • share 
  • tweet  
  • share 

Category iconHealthcare & Lifesciences,  International Intellectual Property,  Patent Law Tag iconPatent,  ECJ,  Gilead,  SPC,  TEVA,  Mylan,  basis patent,  claims,  active substances,  Aids-Blockbuster,  pre-exposure prophylaxis (PREP),  prep

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law
This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Recent Posts

  • Chianti vs GHISU: advantage taken unfairly of the earlier mark 15. April 2021
  • ECJ on legitimate interest: Appeal against amendment of specifications 15. April 2021
  • Case law product similarity: consumer attention 13. April 2021
  • OLG Düsseldorf: No compensation for damages of gratuitous licensing 9. April 2021

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

8. April 2021
Hitachi patent partially invalid in GER: code distribution for mobile communication

Hitachi patent partially invalid in GER: code distribution for mobile communication

6. April 2021
Google vs. Oracle: Java API code falls under fair use!

Google vs. Oracle: Java API code falls under fair use!

29. March 2021
EuGH / Case Lundbeck:  Restriction by object

EuGH / Case Lundbeck: Restriction by object

23. March 2021
ECJ: Digital framing of works protected by copyright

ECJ: Digital framing of works protected by copyright

23. March 2021
Employee’s invention with software

Employee’s invention with software

22. March 2021
EPO Statistics: Western world less innovative

EPO Statistics: Western world less innovative

Footer

Contact

Franklinstr. 61-63
D-60486 Frankfurt am Main
Germany

+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Customer Reviews

Meyer-Dulheuer MD Legal Patentanwälte PartG mbB Patentrecht, Markenrecht, Eigentum hat 4,78 von 5 Sternen 23 Bewertungen auf ProvenExpert.com

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Info secure emails
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • xing
  • Email

Newsletter Signup

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form